Related Experiment Videos
Effectiveness of eletriptan in reducing time loss caused by migraine attacks.
1Pfizer Central Research, Sandwich, England. Nicholas_Wells@Sandwich.Pfizer.com
Pharmacoeconomics
|March 3, 2001
Summary
Eletriptan significantly reduces lost time from usual activities during migraine attacks. This migraine treatment offers substantial patient benefits by restoring daily functioning more quickly than placebo.
Area of Science:
- Neurology
- Pharmacology
- Health Economics
Background:
- Migraine attacks cause significant personal and societal burdens.
- Direct healthcare costs of migraine are often lower than productivity losses.
Purpose of the Study:
- To evaluate eletriptan's effectiveness in reducing migraine-related functional impairment.
- To assess the impact of eletriptan on time lost from usual activities during a migraine attack.
Main Methods:
- A multinational, randomized, placebo-controlled phase III trial.
- 692 patients received eletriptan (40 mg or 80 mg) or placebo for a migraine attack.
- Time lost from usual activities was self-reported via diary 24 hours post-dose.
Main Results:
- Eletriptan users lost a median of 4 hours from usual activities versus 9 hours for placebo (p < 0.001).
- Significant reduction in functional impairment was observed with both eletriptan doses.
- Time savings correlated with improved clinical efficacy findings.
Conclusions:
- Eletriptan significantly reduces the time patients are unable to perform usual activities during a migraine attack.
- This functional improvement represents a substantial benefit for individuals with migraine.
- Further research is needed to fully quantify the economic value of these gains.